CENTOGENE Receives Delisting Notice From Nasdaq
07 août 2024 18h19 HE
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases,...
CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors
01 août 2024 16h15 HE
|
Centogene NV
Initial data from largest international Parkinson’s disease patient cohort shows approximately 90% of these genetically confirmed patients had variants in the LRRK2 or GBA1 genes, making these...
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
20 juin 2024 08h00 HE
|
Centogene NV
TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug...
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
31 mai 2024 16h30 HE
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare...
CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
15 mai 2024 17h17 HE
|
Centogene NV
Reported Full Year 2023 total revenues of 2% growth at €48.5 millionSecured approximately USD 20 million – strengthening cash position and expanding relationship with Lifera, a biopharma company owned...
CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position
15 mai 2024 17h10 HE
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
14 mai 2024 08h30 HE
|
Centogene NV
CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical researchCompanies amend existing drug discovery partnership for Evotec to lead continued...
CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
10 mai 2024 06h30 HE
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 10, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE Receives Nasdaq Non-Compliance Notice
02 avr. 2024 16h30 HE
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 02, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“Centogene”, “we”, or the “Company”), the essential life science partner for...
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
19 mars 2024 06h30 HE
|
Centogene NV
Longstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 19, 2024 ...